Project Grant R01HL182914
Award Date 5/1/26
Completion Date 2/28/31
Dollars Obligated $868K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $1.32 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) on August 18, 2025, to conduct the CARDAMOM (Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia) study. The award funds a randomized, double-blind clinical trial designed to investigate whether mineralocorticoid receptor (MR) antagonism improves cardiac...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a research project examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling. The project, which will extend through February 28, 2031, investigates whether systolic blood pressure indexed to oxygen consumption...
- Federal Grant Award Summary Massachusetts General Hospital received a $249,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective April 1, 2026 through March 31, 2029. This award supports whole genome sequence interpretation research focused on discovering new genes and mechanisms associated with coronary artery disease (CAD) and familial hypercholesterolemia (FH). The research addresses...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $247,500 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025 through August 31, 2027. The award supports research to develop a non-invasive biomarker-based classifier model for early detection of pulmonary vascular dysfunction (PVD) in acute respiratory distress syndrome (ARDS) patients. ARDS patients with PVD...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $739,474 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) on August 18, 2025, to investigate the anti-fibrotic roles of stress-induced tRNA-derived small RNAs (tDRs) in cardiac fibrosis. The research will be conducted through May 31, 2030, and focuses on characterizing the mechanisms by which ASP-GTC-3' tDR, a regulatory RNA fragment derived from transfer RNA,...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital $805,921 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research investigating respiratory disease mechanisms through integrated analysis of genomic and functional data. This project grant, which extends through June 30, 2030, will deliver comprehensive genetic and multi-omic research services focused on deciphering shared...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $773,479 Project Grant to Harvard College's Office for Sponsored Programs on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into mitochondrial gene editing in human cardiomyocytes, with completion anticipated by May 31, 2029. The project delivers a novel Cas9-based mitochondrial gene editor system (MEDITORS) designed to introduce, regulate, and...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $667,776 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) on June 15, 2025, with completion scheduled for April 30, 2030. The award funds clinical research to generate evidence on the effectiveness and appropriate use of antenatal late preterm steroids (ALPS) in reducing neonatal respiratory morbidity among infants born between 34-36 weeks of...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $855,585 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on August 20, 2025, with an expected completion date of July 31, 2028. The project focuses on developing and adapting an antihypertensive self-titration intervention for implementation in U.S. primary care settings. Given that nearly one in two American adults has...
- Federal Project Grant Summary Massachusetts General Hospital received a $1.52M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with a completion date of June 30, 2029. The award funds development and clinical validation of mechanomicroscopy, an innovative endoscopic imaging platform designed to enable transbronchial assessment of pulmonary hypertension (PH) due to lung disease....